COVID-19中的凝血病
基于近期报告,COVID-19最严重患者常出现凝血病和类似弥散性血管内凝血(DIC)的血管内大量血栓形成,凝血检测或有助于识别重症病例。以D-二聚体和纤维蛋白/纤维蛋白原降解产物升高为特征的变化提示凝血病本质是大量纤维蛋白形成,其机制尚未完全阐明,出血倾向不常见但血栓发生率及标准静脉血栓栓塞剂量是否充分尚不确定。
要点
- COVID-19重症患者常出现凝血病和类似DIC的血管内大量血栓形成。
- 凝血检测或有助于区分COVID-19重症病例。
- 凝血病以器官功能障碍为主,出血事件较少见。
核心结论
- COVID-19相关凝血病主要表现为器官功能障碍,出血事件较少见。
- 凝血检测或有助于区分COVID-19重症病例。
研究设计与样本
- 基于近期报告的综述。
主要发现
- 与细菌性脓毒症相关凝血病/DIC相比,COVID-19中凝血酶原时间和活化部分凝血活酶时间延长及抗凝血酶活性降低较少见,血小板减少相对不常见。
- 以D-二聚体和纤维蛋白/纤维蛋白原降解产物升高为代表的变化提示凝血病本质是大量纤维蛋白形成。
- 凝血病机制尚未完全阐明,推测涉及炎症细胞因子调控的免疫失调、淋巴细胞死亡、缺氧和内皮损伤。
- 出血倾向不常见,但COVID-19中血栓发生率及当前标准静脉血栓栓塞剂量建议是否充分尚不确定。
局限性
- 凝血病的机制尚未完全阐明。
- COVID-19中血栓发生率及当前标准静脉血栓栓塞剂量建议是否充分尚不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The COVID-19 pandemic has become an urgent issue in every country. Based on recent reports, the most severely ill patients present with coagulopathy, and disseminated intravascular coagulation (DIC)-like massive intravascular clot formation is frequently seen in this cohort. Therefore, coagulation tests may be considered useful to discriminate severe cases of COVID-19. The clinical presentation of COVID-19-associated coagulopathy is organ dysfunction primarily, whereas hemorrhagic events are less frequent. Changes in hemostatic biomarkers represented by increase in D-dimer and fibrin/fibrinogen degradation products indicate the essence of coagulopathy is massive fibrin formation. In comparison with bacterial-sepsis-associated coagulopathy/DIC, prolongation of prothrombin time, and activated partial thromboplastin time, and decrease in antithrombin activity is less frequent and thrombocytopenia is relatively uncommon in COVID-19. The mechanisms of the coagulopathy are not fully elucidated, however. It is speculated that the dysregulated immune responses orchestrated by inflammatory cytokines, lymphocyte cell death, hypoxia, and endothelial damage are involved. Bleeding tendency is uncommon, but the incidence of thrombosis in COVID-19 and the adequacy of current recommendations regarding standard venous thromboembolic dosing are uncertain.
引用
- Iba T, Levy JH, Levi M, et al. Coagulopathy in COVID-19. J Thromb Haemost. 2020. PMID: 32558075. doi:10.1111/jth.14975
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。